SCHEMBL7549393

SCHEMBL7549393

Cc1ccc(-c2ccc(S(=O)(=O)Cl)s2)cc1.Cc1ccc(-c2ccc(S(=O)(=O)Cl)s2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 3/20 0.42
▸ MMP9 P14780 3/20 0.42
▸ PFKFB3 Q16875 1/20 0.41
▸ PFKFB4 Q16877 1/20 0.41
▸ CA12 O43570 5/20 0.41
▸ CA1 P00915 5/20 0.41
▸ CA2 P00918 5/20 0.41
▸ CA9 Q16790 5/20 0.41
▸ HSD17B1 P14061 3/20 0.41
▸ HSD17B2 P37059 3/20 0.41
▸ ESRRG P62508 1/20 0.38
▸ MMP1 P03956 1/20 0.37
▸ MMP13 P45452 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3254332 1.00 MMP2 (0.42) MMP2MMP9PFKFB3PFKFB4CA12
SCHEMBL14569173 0.83 PTGS2 (0.43) MMP2MMP9PFKFB3PFKFB4CA12
SCHEMBL2764152 0.83 IKBKB (0.47) MMP2MMP9CA12CA1CA2
SCHEMBL7336143 0.83 HSD17B1 (0.45) PFKFB3PFKFB4CA12CA1CA2
SCHEMBL6970542 0.83 HSD17B1 (0.45) PFKFB3PFKFB4CA12CA1CA2
SCHEMBL7057540 0.81 KDM4E (0.42) MMP2MMP9CA12CA1CA2
SCHEMBL13743183 0.81 CA2 (0.56) MMP2MMP9PFKFB3PFKFB4CA12
SCHEMBL7056144 0.81 MEN1 (0.49) PFKFB3CA12CA1CA2CA9
SCHEMBL7341689 0.81 CA12 (0.44) PFKFB3CA12CA1CA2CA9
SCHEMBL957340 0.81 CA12 (0.44) PFKFB3CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0980369-A1 SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS TEXAS BIOTECHNOLOGY CORPORATION (US) 2000-02-23 — — EP disclosed
WO-1998049162-A1 SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS TEXAS BIOTECHNOLOGY CORPORATION (US) 1998-11-05 — — WO disclosed
Send feedback